Global Immune Checkpoint Inhibitors Market 2019-2023

Global Immune Checkpoint Inhibitors Market 2019-2023

About this market

The growing number of cancer cases being diagnosed across the globe. Various international and national level campaigns are conducted to increase the awareness about cancer and to help early detection of the disease. Technavio’s analysts have predicted that the immune checkpoint inhibitors market will register a CAGR of almost 3% by 2023.

Market Overview

High target affinity and specificity of immune checkpoint inhibitors drugs

Most of the approved therapies for cancer treatment have severe side effects, which lowers the patient compliance towards the treatment. Thus, these drawbacks help the immune checkpoint inhibitors market grow.

High costs associated with the treatment

Treatment cost is one of the major challenges for cancer patients. The high cost is mainly due to hospitalization, laboratory costs, and novel immunotherapies.

For the detailed list of factors that will drive and challenge the growth of the immune checkpoint inhibitors market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including AstraZeneca and Bristol-Myers Squibb the competitive environment is quite intense. Factors such as the high target affinity and specificity of immune checkpoint inhibitors drugs and the growing number of cancer cases being diagnosed across the globe will provide considerable growth opportunities to immune checkpoint inhibitors manufactures. AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, and F. Hoffmann-La Roche are some of the major companies covered in this report.

‘With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.’


  • Executive summary
  • Scope of the report
  • Market landscape
    • Market ecosystem
      • Table Global oncology drugs market
      • Table Segments of global oncology drugs market
    • Market characteristics
      • Table Market characteristics
    • Market segmentation analysis
      • Table Market segments
  • Market sizing
    • Market definition
      • Table Market definition - Inclusions and exclusions checklist
    • Market sizing 2018
      • Table Market size 2018
    • Market size and forecast 2018-2023
      • Table Global market: Size and forecast 2018-2023 ($ billions)
      • Table Global market: Year-over-year growth 2019-2023 (%)
  • Five forces analysis
    • Table Five forces analysis 2018
    • Table Five forces analysis 2023
    • Bargaining power of buyers
      • Table Bargaining power of buyers
    • Bargaining power of suppliers
      • Table Bargaining power of suppliers
    • Threat of new entrants
      • Table Threat of new entrants
    • Threat of substitutes
      • Table Threat of substitutes
    • Threat of rivalry
      • Table Threat of rivalry
    • Market condition
      • Table Market condition - Five forces 2018
  • Market segmentation by type
    • Table Type - Market share 2018-2023 (%)
    • Comparison by type
      • Table Comparison by type
    • PD-1 inhibitors - Market size and forecast 2018-2023
      • Table PD-1 inhibitors - Market size and forecast 2018-2023 ($ billions)
      • Table PD-1 inhibitors - Year-over-year growth 2019-2023 (%)
    • CTLA-4 inhibitors - Market size and forecast 2018-2023
      • Table CTLA-4 inhibitors - Market size and forecast 2018-2023 ($ billions)
      • Table CTLA-4 inhibitors - Year-over-year growth 2019-2023 (%)
    • Others - Market size and forecast 2018-2023
      • Table Others - Market size and forecast 2018-2023 ($ billions)
      • Table Others - Year-over-year growth 2019-2023 (%)
    • Market opportunity by type
      • Table Market opportunity by type
  • Customer landscape
    • Table Customer landscape
  • Geographic landscape
    • Geographic segmentation
      • Table Market share by geography 2018-2023 (%)
    • Geographic comparison
      • Table Geographic comparison
    • Americas - Market size and forecast 2018-2023
      • Table Americas - Market size and forecast 2018-2023 ($ billions)
      • Table Americas - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in Americas
    • EMEA - Market size and forecast 2018-2023
      • Table EMEA - Market size and forecast 2018-2023 ($ billions)
      • Table Patient assistance program by AstraZeneca
      • Table EMEA - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in EMEA
    • APAC - Market size and forecast 2018-2023
      • Table APAC - Market size and forecast 2018-2023 ($ billions)
      • Table APAC - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in APAC
    • Key leading countries
      • Table Key leading countries
    • Market opportunity
      • Table Market opportunity
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Patient assistance programs
      • Table Combined action of PD-1 and CTLA-4 checkpoint inhibitors
    • Market challenges
      • Table Treatment costs of immune checkpoint inhibitor therapeutics in US
      • Table Side effects of immune checkpoint inhibitors
      • Table Impact of drivers and challenges
  • Market trends
    • Table Some of the strategic alliances in global immune checkpoint inhibitors market
    • Table Approved drugs with respect to their cancer indications
    • Table Expansion of research areas of approved drugs
  • Vendor landscape
    • Overview
      • Table Vendor landscape
    • Landscape disruption
      • Table Landscape disruption
    • Competitive scenario
  • Vendor analysis
    • Vendors covered
      • Table Vendors covered
    • Vendor classification
      • Table Vendor classification
    • Market positioning of vendors
      • Table Market positioning of vendors
    • AstraZeneca
      • Table AstraZeneca - Vendor overview
      • Table AstraZeneca - Business segments
      • Table AstraZeneca - Organizational developments
      • Table AstraZeneca - Geographic focus
      • Table AstraZeneca - Segment focus
      • Table AstraZeneca - Key offerings
      • Table AstraZeneca - Key customers
    • Bristol-Myers Squibb
      • Table Bristol-Myers Squibb - Vendor overview
      • Table Bristol-Myers Squibb - Business segments
      • Table Bristol-Myers Squibb - Organizational developments
      • Table Bristol-Myers Squibb - Geographic focus
      • Table Bristol-Myers Squibb - Key offerings
      • Table Bristol-Myers Squibb - Key customers
    • F. Hoffmann-La Roche
      • Table F. Hoffmann-La Roche - Vendor overview
      • Table F. Hoffmann-La Roche - Business segments
      • Table F. Hoffmann-La Roche - Organizational developments
      • Table F. Hoffmann-La Roche - Geographic focus
      • Table F. Hoffmann-La Roche - Segment focus
      • Table F. Hoffmann-La Roche - Key offerings
      • Table F. Hoffmann-La Roche - Key customers
    • Merck Sharp & Dohme
      • Table Merck Sharp & Dohme - Vendor overview
      • Table Merck Sharp & Dohme - Business segments
      • Table Merck Sharp & Dohme - Organizational developments
      • Table Merck Sharp & Dohme - Geographic focus
      • Table Merck Sharp & Dohme - Segment focus
      • Table Merck Sharp & Dohme - Key offerings
      • Table Merck Sharp & Dohme - Key customers
    • Pfizer
      • Table Pfizer - Vendor overview
      • Table Pfizer - Business segments
      • Table Pfizer - Organizational developments
      • Table Pfizer - Geographic focus
      • Table Pfizer - Segment focus
      • Table Pfizer - Key offerings
      • Table Pfizer - Key customers
  • Appendix
    • List of Abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook